Carlsmed Raises $10M to Commercialize Breakthrough aprevo™ Devices
Today, Carlsmed, Inc. announces the close of a $10M Series A financing to commercialize the
aprevo family of spine deformity correction devices. The San Diego-based medical device company is focused on improving outcomes for patients with adult spinal deformity. Carlsmed has pioneered a novel digital + surgical solution to create optimized surgical plans and personalized
aprevo implants to enable superior correction of the spinal deformity. This round of financing is led by U.S. Venture Partners (USVP) and includes participation from The Vertical Group, Cove Fund, and Wavemaker Three-Sixty Health, among others.
This round of financing comes at the perfect time to meet surgeon and patient demand for the newly launched Breakthrough